Johnson & Johnson (NYSE:JNJ) had its price target raised by Jefferies Group LLC from $110.00 to $120.00 in a research report released on Friday. They currently have a hold rating on the stock.
Other research analysts have also recently issued reports about the company. Argus reissued a buy rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Friday, October 21st. Vetr raised Johnson & Johnson from a hold rating to a buy rating and set a $121.49 target price on the stock in a research report on Tuesday, October 18th. RBC Capital Markets set a $133.00 target price on Johnson & Johnson and gave the stock a buy rating in a research report on Wednesday, November 9th. Barclays PLC cut Johnson & Johnson from an overweight rating to an equal weight rating and dropped their target price for the stock from $130.00 to $125.00 in a research report on Tuesday, November 29th. They noted that the move was a valuation call. Finally, Bank of America Corporation reissued a hold rating and issued a $126.00 target price on shares of Johnson & Johnson in a research report on Monday, November 28th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $121.93.
Johnson & Johnson (NYSE:JNJ) opened at 111.29 on Friday. The stock has a market cap of $302.77 billion, a price-to-earnings ratio of 19.53 and a beta of 0.72. Johnson & Johnson has a one year low of $99.78 and a one year high of $126.07. The stock’s 50 day moving average price is $114.82 and its 200 day moving average price is $117.92.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.02. The business had revenue of $18.10 billion for the quarter, compared to analysts’ expectations of $18.28 billion. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period last year, the firm posted $1.44 earnings per share. Equities analysts predict that Johnson & Johnson will post $6.71 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 14th. Investors of record on Tuesday, February 28th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Friday, February 24th. Johnson & Johnson’s payout ratio is currently 56.64%.
A number of institutional investors have recently bought and sold shares of the stock. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth about $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter worth about $103,000. Itau Unibanco Holding S.A. acquired a new position in Johnson & Johnson during the third quarter worth about $104,000. Live Your Vision LLC acquired a new position in Johnson & Johnson during the third quarter worth about $113,000. Finally, Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the last quarter. Institutional investors own 65.28% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.